Cannabis-medicine leader Avextra partners with SynQube for accelerated drug development in 2025.
Avextra AG, Europe's cannabis-based medicine leader, partners with SynQube GmbH, bringing 25+ years of cannabinoid & psychotropic substance expertise. The partnership aims to accelerate safe, innovative drug development for unmet patient needs, including a multicenter trial starting in 2025. Avextra and SynQube will leverage combined expertise to deliver high-quality drugs in the pharmaceutical industry.
June 20, 2024
3 Articles